ライフサイエンスコーパス: plasma glucagon

1 ypoglycemia produced a threefold increase in plasma glucagon.

2 ively, P < 0.05 for both) and no increase in plasma glucagon.

3 increased ( approximately 10-fold) levels of plasma glucagon.

4 ever, produced a more pronounced blunting of plasma glucagon, ACTH, and hepatic glucose production co

5 There was a prompt rise in plasma glucagon after intravenous arginine in all groups

6 ng antibody to healthy individuals increased plasma glucagon and amino acid levels, but did not chang

7 sociated with decreased food intake, reduced plasma glucagon and corticosterone concentrations, and d

8 only slightly, it fully normalized elevated plasma glucagon and corticosterone levels and reversed t

9 ose, plasma lipids, liver triglycerides, and plasma glucagon and enhanced pancreatic insulin content,

10 OXA infusion increases plasma glucagon and glucose levels and decreases plasma

11 lerance in Pemt(-/-) mice through modulating plasma glucagon and its action in liver.

12 -/-) mice have elevated ( approximately 60%) plasma glucagon and reduced ( approximately 20%) plasma

13 lucose and was accompanied by lowered HbA1c, plasma glucagon, and triglyceride concentrations and exp

14 fatty acid was accompanied by a fall in the plasma glucagon concentration from 122 to 85 pmol/L (P =

15 nd was accompanied by an increase in fasting plasma glucagon concentration.

16 results in higher plasma glucose and higher plasma glucagon concentrations after a mixed meal and af

17 sfunction, characterized by elevated fasting plasma glucagon concentrations and inadequate postprandi

18 In humans, postprandial lipemia increased plasma glucagon concentrations and led to an inadequate

19 We measured plasma glucagon concentrations in patients with type 1 d

20 Plasma glucagon concentrations were suppressed by -13 +/

21 - 77 pmol/l), but there was no difference in plasma glucagon concentrations.

22 hours and were independent of any changes in plasma glucagon concentrations; these effects were abrog

23 Arterial plasma glucagon decreased from 54 +/- 7 to 32 +/- 3 ng/l

24 nd the hepatic portal-arterial difference in plasma glucagon decreased slightly from 41 +/- 7 and 4 +

25 whether macronutrient infusion can suppress plasma glucagon during critical illness and study the ro

26 Both groups had significant rises in plasma glucagon during the hypoglycemic clamp similar to

27 In patients with diabetes, elevations in plasma glucagon, epinephrine, and norepinephrine were bl

28 /- 6 pM), suppression of glucagon secretion (plasma glucagon, I:31 +/- 4, II: 63 +/- 8 pg/ml) doubled

29 nd the hepatic portal-arterial difference in plasma glucagon increased from 43 +/- 5 and 4 +/- 2 to 5

30 Plasma glucagon increased in the control study from 44 +

31 his pattern of change mirrored precisely the plasma glucagon/insulin ratio.

32 tor monoclonal antibody undergo elevation of plasma glucagon levels and alpha-cell expansion similar

33 effect associated with normalization of both plasma glucagon levels and hepatic expression of glucone

34 The arterial plasma glucagon levels and the hepatic portal-arterial d

35 plus xenin-25 transiently increased ISR and plasma glucagon levels in subjects with NGT and IGT but

36 lasma triglyceride levels, but did not alter plasma glucagon levels or alpha-cell mass.

37 As expected, plasma glucagon levels were elevated in STZ-DM rats, and

38 were associated with protein breakdown, and plasma glucagon levels were inversely correlated with pr

39 Xenin-25 alone had no effect on ISRs or plasma glucagon levels, but the combination of GIP plus

40 e-stimulated insulin secretion, and elevated plasma glucagon levels.

41 In contrast, AR231453 increased plasma glucagon-like peptide 1 (GLP-1) and insulin level

42 Antropyloroduodenal pressures, plasma glucagon-like peptide 1 (GLP-1), cholecystokinin,

43 Fasting and postprandial plasma glucagon-like peptide 1 (GLP-1), peptide YY (PYY)

44 Sitagliptin increased plasma glucagon-like peptide-1 (7-36) levels and, at pea

45 sulin secretion (P < .01), and 3-fold larger plasma glucagon-like peptide-1(7-36) (GLP-1(7-36)) excur

46 nd the hepatic portal-arterial difference in plasma glucagon (ng/l) did not change significantly (43

47 nd the hepatic portal-arterial difference in plasma glucagon (ng/l) did not rise significantly (40 +/

48 nd the hepatic portal-arterial difference in plasma glucagon (ng/l) rose from 43 +/- 5 and 5 +/- 2 to

49 As expected, plasma glucagon (P = 0.0094), epinephrine (P = 0.0063),

50 tradiol also attenuated hypoglycemia-induced plasma glucagon, pituitary proopiomelanocortin (POMC), a

51 he great potential that normalization of the plasma glucagon profile may have for the treatment of T2

52 Arterial plasma glucagon rose to a similar maximum in CON (73 +/-

53 We applied novel analytical methods of plasma glucagon (sandwich ELISA and mass spectrometry-ba

54 Plasma glucagon was elevated in Pemt(-/-) mice fed the H

55 Serum insulin was decreased, and plasma glucagon was increased.

56 ticosteroid levels were altered as expected, plasma glucagon was reduced markedly in the mutant anima

57 were greater with ID4 than ID2, as was GIGD; plasma glucagon was suppressed by ID2, but not ID4.